Literature DB >> 34778796

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.

Antoni Ribas1, Madhav V Dhodapkar2, Katie M Campbell3, Faith E Davies4,5, Steven D Gore5,6, Ronald Levy5,7, Lee M Greenberger8.   

Abstract

Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34778796      PMCID： PMC8580613          DOI： 10.1158/2643-3230.BCD-21-0166

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  30 in total

1.  Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.

Authors:  Thomas A Ollila; Shaolei Lu; Rebecca Masel; Adam Zayac; Kimberly Paiva; Ralph D Rogers; Adam J Olszewski
Journal:  JAMA Oncol       Date:  2021-11-01       Impact factor: 33.006

2.  Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2.

Authors:  Benjamin Israelow; Tianyang Mao; Jonathan Klein; Eric Song; Bridget Menasche; Saad B Omer; Akiko Iwasaki
Journal:  Sci Immunol       Date:  2021-09-02

3.  COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

Authors:  Lindsey E Roeker; David A Knorr; Meghan C Thompson; Mariely Nivar; Sonia Lebowitz; Nicole Peters; Isaac Deonarine; Saddia Momotaj; Saumya Sharan; Vanessa Chanlatte; Bianca Hampton; Liana Butala; Lindsay Amato; Angela Richford; Jessica Lunkenheimer; Kristen Battiato; Carissa Laudati; Anthony R Mato
Journal:  Leukemia       Date:  2021-05-13       Impact factor: 11.528

4.  Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.

Authors:  Paola Ghione; Juan J Gu; Kristopher Attwood; Pallawi Torka; Shipra Goel; Suchitra Sundaram; Cory Mavis; Michael Johnson; Roshneke Thomas; Kenneth Michael McWhite; Andrea Darrall; Joseph DeMarco; Jessica Kostrewa; Alice Mohr; Leah Rivas; Mirdza Neiders; Lakshmanan Suresh; Brahm H Segal; Elizabeth A Griffiths; Vincent Ramsperger; Long Shen; Francisco J Hernandez-Ilizaliturri
Journal:  Blood       Date:  2021-06-29       Impact factor: 22.113

5.  CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Authors:  Erin M Bange; Nicholas A Han; Paul Wileyto; Justin Y Kim; Sigrid Gouma; James Robinson; Allison R Greenplate; Madeline A Hwee; Florence Porterfield; Olutosin Owoyemi; Karan Naik; Cathy Zheng; Michael Galantino; Ariel R Weisman; Caroline A G Ittner; Emily M Kugler; Amy E Baxter; Olutwatosin Oniyide; Roseline S Agyekum; Thomas G Dunn; Tiffanie K Jones; Heather M Giannini; Madison E Weirick; Christopher M McAllister; N Esther Babady; Anita Kumar; Adam J Widman; Susan DeWolf; Sawsan R Boutemine; Charlotte Roberts; Krista R Budzik; Susan Tollett; Carla Wright; Tara Perloff; Lova Sun; Divij Mathew; Josephine R Giles; Derek A Oldridge; Jennifer E Wu; Cécile Alanio; Sharon Adamski; Alfred L Garfall; Laura A Vella; Samuel J Kerr; Justine V Cohen; Randall A Oyer; Ryan Massa; Ivan P Maillard; Kara N Maxwell; John P Reilly; Peter G Maslak; Robert H Vonderheide; Jedd D Wolchok; Scott E Hensley; E John Wherry; Nuala J Meyer; Angela M DeMichele; Santosha A Vardhana; Ronac Mamtani; Alexander C Huang
Journal:  Nat Med       Date:  2021-05-20       Impact factor: 87.241

6.  Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.

Authors:  Antoni Ribas; Rajarshi Sengupta; Trevan Locke; Sayyed Kaleem Zaidi; Katie M Campbell; John M Carethers; Elizabeth M Jaffee; E John Wherry; Jean-Charles Soria; Gypsyamber D'Souza
Journal:  Cancer Discov       Date:  2020-12-19       Impact factor: 38.272

7.  Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.

Authors:  Evangelos Terpos; Ioannis P Trougakos; Maria Gavriatopoulou; Ioannis Papassotiriou; Aimilia D Sklirou; Ioannis Ntanasis-Stathopoulos; Eleni-Dimitra Papanagnou; Despina Fotiou; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood       Date:  2021-07-01       Impact factor: 22.113

8.  Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.

Authors:  Irit Avivi; Roi Balaban; Tamir Shragai; Gabi Sheffer; Miguel Morales; Anat Aharon; Noa Lowenton-Spier; Svetlana Trestman; Chava Perry; Noam Benyamini; Moshe Mittelman; Yaara Tabib; Tali Bar Lev; Mor Zavaro; Yair Herishanu; Efrat Luttwak; Yael C Cohen
Journal:  Br J Haematol       Date:  2021-07-01       Impact factor: 8.615

9.  Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.

Authors:  Susanne Ghandili; Martin Schönlein; Marc Lütgehetmann; Julian Schulze Zur Wiesch; Heiko Becher; Carsten Bokemeyer; Marianne Sinn; Katja C Weisel; Lisa B Leypoldt
Journal:  Cancers (Basel)       Date:  2021-07-28       Impact factor: 6.639
View more
  8 in total

1.  Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.

Authors:  Jane C Figueiredo; Fred R Hirsch; Lawrence H Kushi; Wendy N Nembhard; James M Crawford; Nicholas Mantis; Laurel Finster; Noah M Merin; Akil Merchant; Karen L Reckamp; Gil Y Melmed; Jonathan Braun; Dermot McGovern; Samir Parekh; Douglas A Corley; Namvar Zohoori; Benjamin C Amick; Ruofei Du; Peter K Gregersen; Betty Diamond; Emanuela Taioli; Carlos Sariol; Ana Espino; Daniela Weiskopf; Alba Gifoni; James Brien; William Hanege; Marc Lipsitch; David A Zidar; Ann Scheck McAlearney; Ania Wajnberg; Joshua LaBaer; E Yvonne Lewis; Raquel A Binder; Ann M Moormann; Catherine Forconi; Sarah Forrester; Jennifer Batista; John Schieffelin; Dongjoo Kim; Giulia Biancon; Jennifer VanOudenhove; Stephanie Halene; Rong Fan; Dan H Barouch; Galit Alter; Swetha Pinninti; Suresh B Boppana; Sunil K Pati; Misty Latting; Andrew H Karaba; John Roback; Rafick Sekaly; Andrew Neish; Ahnalee M Brincks; Douglas A Granger; Amy B Karger; Bharat Thyagarajan; Stefani N Thomas; Sabra L Klein; Andrea L Cox; Todd Lucas; Debra Furr-Holden; Kent Key; Nicole Jones; Jens Wrammerr; Mehul Suthar; Serre Yu Wong; Natalie M Bowman; Viviana Simon; Lynne D Richardson; Russell McBride; Florian Krammer; Meenakshi Rana; Joshua Kennedy; Karl Boehme; Craig Forrest; Steve W Granger; Christopher D Heaney; Maria Knight Lapinski; Shannon Wallet; Ralph S Baric; Luca Schifanella; Marcos Lopez; Soledad Fernández; Eben Kenah; Ashish R Panchal; William J Britt; Iñaki Sanz; Madhav Dhodapkar; Rafi Ahmed; Luther A Bartelt; Alena J Markmann; Jessica T Lin; Robert S Hagan; Matthew C Wolfgang; Jacek Skarbinski
Journal:  Open Forum Infect Dis       Date:  2022-04-27       Impact factor: 4.423

Review 2.  Vaccination for SARS-CoV-2 in Hematological Patients.

Authors:  Niccolò Riccardi; Marco Falcone; Dafna Yahav
Journal:  Acta Haematol       Date:  2022-02-25       Impact factor: 3.068

3.  Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

Authors:  Andres Chang; Akil Akhtar; Susanne L Linderman; Lilin Lai; Victor M Orellana-Noia; Rajesh Valanparambil; Hasan Ahmed; Veronika I Zarnitsyna; Ashley A McCook-Veal; Jeffrey M Switchenko; Jean L Koff; Kristie A Blum; Amy A Ayers; Colin B O'Leary; Michael C Churnetski; Shahana Sulaiman; Melissa Kives; Preston Sheng; Carl W Davis; Ajay K Nooka; Rustom Antia; Madhav V Dhodapkar; Mehul S Suthar; Jonathon B Cohen; Rafi Ahmed
Journal:  J Clin Oncol       Date:  2022-04-18       Impact factor: 50.717

4.  Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.

Authors:  Cristina Bergamaschi; Maria Pagoni; Margherita Rosati; Matthew Angel; Ifigeneia Tzannou; Margarita Vlachou; Ismini Darmani; Amirah Ullah; Jenifer Bear; Santhi Devasundaram; Robert Burns; Ioannis Baltadakis; Stavros Gigantes; Meletios-Athanasios Dimopoulos; George N Pavlakis; Evangelos Terpos; Barbara K Felber
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

5.  mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients.

Authors:  Elena Azzolini; Chiara Pozzi; Luca Germagnoli; Bianca Oresta; Nicola Carriglio; Mariella Calleri; Carlo Selmi; Maria De Santis; Silvia Finazzi; Carmelo Carlo-Stella; Alexia Bertuzzi; Francesca Motta; Angela Ceribelli; Alberto Mantovani; Fabrizio Bonelli; Maria Rescigno
Journal:  Life Sci Alliance       Date:  2022-02-15

6.  Danger ahead: COVID-19 infections after vaccination.

Authors:  Lee M Greenberger; Gwen L Nichols
Journal:  Blood       Date:  2022-03-10       Impact factor: 22.113

7.  Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.

Authors:  Thomas A Ollila; Rebecca H Masel; John L Reagan; Shaolei Lu; Ralph D Rogers; Kimberly J Paiva; Rashida Taher; Ella Burguera-Couce; Adam S Zayac; Inna Yakirevich; Rabin Niroula; Peter Barth; Adam J Olszewski
Journal:  Cancer       Date:  2022-07-11       Impact factor: 6.921

Review 8.  COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.

Authors:  Annika Fendler; Elisabeth G E de Vries; Corine H GeurtsvanKessel; John B Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal
Journal:  Nat Rev Clin Oncol       Date:  2022-03-11       Impact factor: 65.011
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.